You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 269 No. 12, March 24, 1993 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Second-Opinion Trial in Patients Recommended for Coronary Angiography

Benjamin S. Warfel, MD
The New York (NY) Hospital Cornell Medical Center

JAMA. 1993;269(12):1504.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The recent study by Graboys et al1 regarding the prevalence of unnecessary coronary angiography is a timely one. Last month, three cases appeared in the literature of a complication following femoral vessel catheterization for angiographic procedures: delayed-onset femoral nerve palsy secondary to iliac hematoma.2,3 The result was severe quadriceps paresis with long-term impairment. The risk of local complication is worth noting when discussing the overall necessity of this procedure, especially in patients without coagulation. . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.